Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/MAP2K3_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/MAP2K3_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/MAP2K3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/MAP2K3_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/MAP2K3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/MAP2K3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005140318 | Esophagus | ESCC | stress-activated MAPK cascade | 147/8552 | 239/18723 | 5.43e-07 | 7.18e-06 | 147 |
GO:004586018 | Esophagus | ESCC | positive regulation of protein kinase activity | 219/8552 | 386/18723 | 6.91e-06 | 6.97e-05 | 219 |
GO:003367420 | Esophagus | ESCC | positive regulation of kinase activity | 260/8552 | 467/18723 | 7.26e-06 | 7.22e-05 | 260 |
GO:00075699 | Esophagus | ESCC | cell aging | 81/8552 | 132/18723 | 2.00e-04 | 1.27e-03 | 81 |
GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
GO:00182124 | Esophagus | ESCC | peptidyl-tyrosine modification | 202/8552 | 378/18723 | 1.34e-03 | 6.39e-03 | 202 |
GO:00181084 | Esophagus | ESCC | peptidyl-tyrosine phosphorylation | 200/8552 | 375/18723 | 1.60e-03 | 7.45e-03 | 200 |
GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
GO:009013220 | Esophagus | ESCC | epithelium migration | 188/8552 | 360/18723 | 6.96e-03 | 2.54e-02 | 188 |
GO:009013020 | Esophagus | ESCC | tissue migration | 190/8552 | 365/18723 | 7.91e-03 | 2.82e-02 | 190 |
GO:00353297 | Esophagus | ESCC | hippo signaling | 26/8552 | 40/18723 | 1.08e-02 | 3.66e-02 | 26 |
GO:00903984 | Esophagus | ESCC | cellular senescence | 54/8552 | 93/18723 | 1.08e-02 | 3.67e-02 | 54 |
GO:000756812 | Liver | Cirrhotic | aging | 117/4634 | 339/18723 | 3.13e-05 | 3.91e-04 | 117 |
GO:003109812 | Liver | Cirrhotic | stress-activated protein kinase signaling cascade | 83/4634 | 247/18723 | 1.04e-03 | 7.28e-03 | 83 |
GO:005140312 | Liver | Cirrhotic | stress-activated MAPK cascade | 80/4634 | 239/18723 | 1.43e-03 | 9.54e-03 | 80 |
GO:000166712 | Liver | Cirrhotic | ameboidal-type cell migration | 145/4634 | 475/18723 | 2.23e-03 | 1.36e-02 | 145 |
GO:00106327 | Liver | Cirrhotic | regulation of epithelial cell migration | 93/4634 | 292/18723 | 3.46e-03 | 1.92e-02 | 93 |
GO:00106317 | Liver | Cirrhotic | epithelial cell migration | 110/4634 | 357/18723 | 5.14e-03 | 2.65e-02 | 110 |
GO:00353311 | Liver | Cirrhotic | negative regulation of hippo signaling | 8/4634 | 13/18723 | 5.27e-03 | 2.70e-02 | 8 |
GO:00901327 | Liver | Cirrhotic | epithelium migration | 110/4634 | 360/18723 | 6.79e-03 | 3.35e-02 | 110 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAP2K3 | SNV | Missense_Mutation | rs748513234 | c.466G>T | p.Asp156Tyr | p.D156Y | P46734 | protein_coding | deleterious(0) | possibly_damaging(0.526) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP2K3 | SNV | Missense_Mutation | novel | c.545N>A | p.Ser182Asn | p.S182N | P46734 | protein_coding | tolerated(0.1) | benign(0.034) | TCGA-D8-A1XR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
MAP2K3 | SNV | Missense_Mutation | rs148304866 | c.455N>A | p.Arg152Gln | p.R152Q | P46734 | protein_coding | deleterious(0.02) | benign(0.003) | TCGA-JL-A3YW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MAP2K3 | insertion | Frame_Shift_Ins | novel | c.900_901insATAAAGGAGTACGAGGTTGAAGG | p.Phe301IlefsTer14 | p.F301Ifs*14 | P46734 | protein_coding | | | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
MAP2K3 | SNV | Missense_Mutation | | c.778N>C | p.Glu260Gln | p.E260Q | P46734 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
MAP2K3 | SNV | Missense_Mutation | | c.50N>C | p.Gly17Ala | p.G17A | P46734 | protein_coding | tolerated(0.54) | benign(0.033) | TCGA-FU-A2QG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAP2K3 | SNV | Missense_Mutation | novel | c.140G>T | p.Arg47Leu | p.R47L | P46734 | protein_coding | tolerated(0.07) | benign(0.137) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAP2K3 | SNV | Missense_Mutation | | c.1028T>C | p.Leu343Pro | p.L343P | P46734 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP2K3 | SNV | Missense_Mutation | rs775653621 | c.119N>A | p.Pro40His | p.P40H | P46734 | protein_coding | deleterious(0) | possibly_damaging(0.819) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAP2K3 | SNV | Missense_Mutation | | c.931N>T | p.Ala311Ser | p.A311S | P46734 | protein_coding | tolerated(0.74) | benign(0.009) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | TRAMETINIB | TRAMETINIB | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | AZD6244 | SELUMETINIB | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | DABRAFENIB MESYLATE | | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | | WX-554 | WX-554 | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | MEK162 | BINIMETINIB | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | | ROSIGLITAZONE | ROSIGLITAZONE | 11591391 |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | BAY869766 | | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | GDC-0973 | COBIMETINIB | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | 178102628 | | |
5606 | MAP2K3 | KINASE, DRUGGABLE GENOME, TRANSPORTER, ENZYME, SERINE THREONINE KINASE, TYROSINE KINASE | inhibitor | SELUMETINIB | SELUMETINIB | |